Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.96 USD | +0.77% | -3.05% | -3.01% |
Financials (USD)
Sales 2024 * | 31.42M | Sales 2025 * | 121M | Capitalization | 1.78B |
---|---|---|---|---|---|
Net income 2024 * | -312M | Net income 2025 * | -251M | EV / Sales 2024 * | 47.4 x |
Net cash position 2024 * | 291M | Net cash position 2025 * | 223M | EV / Sales 2025 * | 12.8 x |
P/E ratio 2024 * |
-5.61
x | P/E ratio 2025 * |
-7.59
x | Employees | 184 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.15% |
Latest transcript on Syndax Pharmaceuticals, Inc.
1 day | +0.77% | ||
1 week | -3.05% | ||
Current month | -11.93% | ||
1 month | -7.17% | ||
3 months | +0.53% | ||
6 months | +82.10% | ||
Current year | -3.01% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Metzger
CEO | Chief Executive Officer | 53 | 15-05-04 |
Peter Ordentlich
FOU | Founder | 55 | 05-10-10 |
Neil Gallagher
PSD | President | 60 | 23-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 17-03-28 |
Dennis Podlesak
CHM | Chairman | 66 | 08-11-30 |
Pierre Legault
BRD | Director/Board Member | 63 | 17-01-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.12% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 20.96 | +0.77% | 665,136 |
24-04-19 | 20.8 | +1.51% | 942,562 |
24-04-18 | 20.49 | -1.21% | 1,223,522 |
24-04-17 | 20.74 | -2.54% | 1,783,012 |
24-04-16 | 21.28 | -1.57% | 749,097 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.01% | 1.78B | |
-0.02% | 42.11B | |
+46.06% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |
- Stock Market
- Equities
- SNDX Stock